Axonics Announces CFO Retirement and Appoints Successor
21 August 2023 - 12:00PM
Business Wire
Axonics, Inc. (Nasdaq: AXNX), a global medical technology
company that is developing and commercializing novel products for
the treatment of bladder and bowel dysfunction, today announced
that Dan L. Dearen, president and chief financial officer, is
retiring from the company. Kari Keese, vice president of finance
and accounting, will succeed Mr. Dearen on Monday, October 2.
“On behalf of the Axonics team and the board of directors, I
want to thank Dan, my co-founder and longtime colleague, for his
many contributions to the company over the last 10 years,” said
Raymond W. Cohen, chief executive officer. “Dan has played an
instrumental role in Axonics’ success and the significant value
that has been created for the company’s shareholders. We wish Dan
all the best on his retirement.”
Mr. Dearen said, “It has been a privilege working alongside the
talented, mission-driven team at Axonics. I am incredibly proud of
the impact the company’s therapies have had on improving the
quality of life for tens of thousands of incontinence patients. I
will follow Axonics with pride as it continues on its path to
market leadership.”
Ms. Keese leads the company’s finance and accounting functions.
She joined Axonics in 2014 and previously served as the company’s
director of finance and controller. Prior to Axonics, Ms. Keese was
controller at Vessix Vascular, Inc., a company led by Mr. Cohen and
Mr. Dearen that was acquired by Boston Scientific in late 2012 and
began her career in public accounting. Ms. Keese is a certified
public accountant and holds a Bachelor of Arts degree in business
economics from University of California, Santa Barbara and a
management certification from UCLA Anderson School of
Management.
Mr. Cohen added, “Kari has been with Axonics for over nine years
and has served as a valuable member of our senior management team.
She is a seasoned executive and we are confident that she will
excel as our next chief financial officer. Kari’s deep knowledge of
the company and track record of financial leadership make her an
ideal successor to Dan.”
Axonics is reaffirming its fiscal year 2023 revenue guidance of
$358 million that was previously provided on July 27, 2023.
About Axonics
Axonics is a global medical technology company that is
developing and commercializing novel products for adults with
bladder and bowel dysfunction. Axonics recently ranked No. 2 on the
2023 Financial Times ranking of the fastest growing companies in
the Americas and No. 4 on the 2022 Deloitte Technology Fast
500.
Axonics® sacral neuromodulation systems provide adults with
overactive bladder and/or fecal incontinence with long-lived, easy
to use, safe, clinically effective therapy. Bulkamid®, the
company’s best-in-class urethral bulking hydrogel, provides safe
and durable symptom relief to women with stress urinary
incontinence. In the U.S., moderate to severe urinary incontinence
affects an estimated 28 million women and fecal incontinence
affects an estimated 19 million adults. For more information, visit
www.axonics.com.
Forward-Looking Statements
Statements made in this press release that relate to future
plans, events, prospects or performance are forward-looking
statements as defined under the Private Securities Litigation
Reform Act of 1995. Words such as “plans,” “expects,” “believes,”
“anticipates,” “designs,” and similar words are intended to
identify forward-looking statements. While these forward-looking
statements are based on the current expectations and beliefs of
management, such forward-looking statements are subject to a number
of risks, uncertainties, assumptions and other factors that could
cause actual results to differ materially from the expectations
expressed in this press release, including the risks and
uncertainties disclosed in Axonics filings with the Securities and
Exchange Commission, all of which are available online at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. Except as required by law, Axonics undertakes no obligation
to update or revise any forward-looking statements to reflect new
information, changed circumstances or unanticipated events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230821533525/en/
Axonics contact: Neil Bhalodkar 949-336-5293
IR@axonics.com
Axonics (NASDAQ:AXNX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Axonics (NASDAQ:AXNX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024